Last Update 02 Jun 26

NAGE: Core Demand And Injectables Will Support Future Buyback Driven Upside

Analysts have trimmed their average price target on Niagen Bioscience by $1 to $12.60, reflecting updated models that incorporate modest adjustments to discount rates, revenue growth, profit margin assumptions, and a slightly lower future P/E multiple.

Analyst Commentary

Recent Street research around Niagen Bioscience centers on how updated models reconcile the current share price with revised assumptions for growth, profitability, and valuation multiples. While the average target has been trimmed, analysts still highlight a mix of supportive and cautionary factors that matter for anyone tracking the stock.

Bullish Takeaways

Some bullish analysts point to what they describe as strong demand in the core business, which they view as a supportive pillar for revenue forecasts even as valuation assumptions are adjusted.
Potential upside from the injectable business is seen as an additional growth lever, and is being factored into models as an option on future expansion rather than a fully priced-in driver.
Maintaining positive ratings alongside lower targets suggests bullish analysts see the revised P/E assumptions and updated cash flow forecasts as still consistent with what they view as an attractive risk reward profile.
The move to a US$13 target from US$14 earlier in the year, alongside the latest US$12.60 average, indicates that at least some of the execution and product pipeline questions are already reflected in price target resets.

Bearish Takeaways

Bearish analysts are marking down targets by US$1 to US$3, tying those changes to more conservative views on revenue growth, profit margins, and appropriate future P/E multiples.
The use of higher discount rates and slightly lower valuation multiples signals increased caution around risk, which can cap how much upside these analysts are willing to assign in their models.
Target cuts following recent quarterly results show that, despite solid demand in some areas, analysts remain watchful on execution, especially around how quickly the injectable business can contribute meaningfully to earnings.
The clustering of lower targets across multiple firms suggests a tighter range of expected outcomes, which could limit how aggressively some bearish analysts are prepared to model longer term growth or profitability improvements.

What's in the News

Niagen Bioscience increased its equity buyback authorization by US$10 million on March 19, 2026, bringing the total program size to US$20 million, and reported completing repurchases of 525,539 shares for US$2.61 million under the authorization announced on November 6, 2025. (Source: Company buyback updates)
Between January 1, 2026 and March 31, 2026, the company repurchased 489,699 shares, representing 0.61%, for US$2.36 million as part of the same buyback program. (Source: Company buyback tranche update)
Niagen Bioscience launched its clinician-directed Niagen Plus telehealth platform in the U.S., giving eligible patients at home access to prescription-only, pharmaceutical grade Niagen via the Niagen At Home Injection Kit, which was generally considered safe and well tolerated in a clinical safety trial. (Source: Product related announcement)
The company announced a partnership with Olympia Pharmaceuticals, an FDA registered 503B outsourcing facility, to compound and distribute pharmaceutical grade Niagen for Niagen Plus intravenous and injectable products, expanding its 503B network alongside Wells Pharma of Houston. (Source: Strategic alliance announcement)
Niagen Bioscience provided 2026 net sales guidance and stated that it expects year over year net sales to be between 10% and 15% higher, excluding 2025 revenue from the Analytical Reference Standards and Services segment, with management pointing to e commerce and new partnerships as key drivers. (Source: Corporate guidance)

Valuation Changes

Fair Value: Modelled fair value remains at $12.60, with no change between the prior and updated estimates.
Discount Rate: The discount rate has risen slightly from 7.30% to about 7.33%, implying a small increase in the required return used in the model.
Revenue Growth: The revenue growth assumption is broadly unchanged, edging up marginally from about 15.99% to about 16.0%.
Net Profit Margin: The net profit margin assumption is effectively flat, easing fractionally from about 16.88% to about 16.88%.
Future P/E: The future P/E multiple has fallen modestly from about 37.1x to about 35.8x, reflecting a slightly lower valuation multiple applied to projected earnings.

0 views

Key Takeaways

Expansion into pharmaceutical-grade Niagen and increased e-commerce performance could drive revenue growth through direct-to-consumer channels and enhanced demand.
Increased R&D investments and legal settlements might strengthen the balance sheet and lead to potential high-margin pharmaceutical developments.
Intense competition, regulatory challenges, and rising expenses could pressure ChromaDex's revenue and margins amidst unresolved supply chain and legal issues.

Catalysts

About ChromaDex

Operates as a bioscience company focusing on developing healthy aging products.What are the underlying business or industry changes driving this perspective?

Expansion into the pharmaceutical-grade Niagen ingredient market, including the launch of Niagen IV and injections at clinics, is expected to drive future revenue growth due to increasing demand and the anticipated resolution of supply chain issues.
Continued e-commerce growth, supported by a significant increase in the Shopify platform's performance and a rising awareness of NAD-boosting products, suggests potential for further revenue growth and improved net margins due to the higher profitability of direct-to-consumer channels.
Planned increases in R&D investments, alongside a potential investigational drug application for the use of NR in the treatment of ataxia telangiectasia, could lead to future earnings growth if successful pharmaceutical developments result in new, high-margin products.
The resolution of reversals of royalty obligations and recoveries from legal settlements contribute to a stronger balance sheet, potentially allowing for reinvestment in growth initiatives and enhancing future net income stability.
The planned company rebranding and name change, aligned with strategic direction, may boost investor interest and market positioning, potentially impacting future revenue by attracting new consumer awareness and business development opportunities.

ChromaDex Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Niagen Bioscience's revenue will grow by 16.0% annually over the next 3 years.
Analysts assume that profit margins will increase from 14.3% today to 16.9% in 3 years time.
Analysts expect earnings to reach $34.4 million (and earnings per share of $0.39) by about June 2029, up from $18.6 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 36.0x on those 2029 earnings, up from 15.5x today. This future PE is greater than the current PE for the US Personal Products industry at 17.3x.
Analysts expect the number of shares outstanding to decline by 0.14% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.33%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Significant competition from companies entering the NAD booster market using practices such as patent infringement, false labeling, and poor manufacturing, which could negatively impact ChromaDex's revenue through increased market dilution.
Supply chain issues, particularly with the pharmaceutical-grade Niagen and the Niagen IV injections, have caused delays and might affect revenue and operational efficiency if not fully resolved.
Dependence on regulatory approvals poses a risk, as any adverse outcome in regulatory reviews or clinical trials (e.g., with the FDA) could hinder product availability and future sales, impacting earnings.
Legal issues, such as the ongoing lawsuit regarding NMN regulations, could impact ChromaDex's products if regulatory outcomes do not favor the company's current strategies, potentially affecting revenue streams.
Increased selling and marketing expenses anticipated in 2025 could pressure net margins if revenue growth does not meet expectations, particularly in the face of intense market competition.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $12.6 for Niagen Bioscience based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $18.0, and the most bearish reporting a price target of just $10.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $203.5 million, earnings will come to $34.4 million, and it would be trading on a PE ratio of 36.0x, assuming you use a discount rate of 7.3%.
Given the current share price of $3.61, the analyst price target of $12.6 is 71.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Niagen Bioscience?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects